KZIA
Kazia Therapeutics Limited
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-16/100
Last price
9.26
▼ 0.09 (0.96%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
9.35
Day high
9.65
Day low
9.18
Volume
129.94K
Market cap
$105.81M
P/E (TTM)
—
52W range
4.86 – 17.40
Trailing performance
Returnvs SPY
1W
-5.03%
-7.0%
1M
-24.78%
-25.9%
3M
-25.68%
-30.2%
6M
-3.74%
-21.9%
YTD
+34.40%
+20.1%
1Y
+41.16%
+24.7%
3Y
-81.48%
-163.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KZIA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.75M
Total on file
Fundamentals
Market cap$105.81M
Enterprise value$35.61M
Revenue (TTM)$1.90M
Gross profit$1.90M
EBITDA$-17.84M
Net income$-22.80M
EPS (TTM)$-6.78
Free cash flow$1.10M
Total cash$69.46M
Total debt$98.81K
Book value / share$2.84
Shares outstanding11.43M
Float9.39M
Short % of float4.95%
Dividend yield0.00%
Beta (5Y)2.27
Valuation & profitability ratios
Trailing P/E—
Forward P/E-777.29
PEG ratio1.01
Price / sales—
Price / book3.26
EV / revenue18.76
EV / EBITDA-2.00
Gross margin100.00%
Operating margin-14641.04%
Profit margin0.00%
Return on equity-106.90%
Return on assets-25.70%
Debt / equity0.21
Current ratio2.87
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $42.00K | $2.31M | $0 | $0 | -98.2% |
| Operating revenue | $42.00K | $2.31M | $0 | $0 | -98.2% |
| Research & development | $7.33M | $17.38M | $15.56M | $20.17M | -57.8% |
| Selling, general & admin | $8.72M | $13.56M | $8.58M | $5.24M | -35.7% |
| Total operating expense | $14.26M | $30.77M | $24.15M | $25.40M | -53.7% |
| Operating income | -$14.22M | -$28.46M | -$24.15M | -$25.40M | +50.0% |
| Net interest income | $72.00K | $12.00K | $22.00K | $2.00K | +500.0% |
| Pre-tax income | -$22.45M | -$27.05M | -$20.74M | -$25.38M | +17.0% |
| Tax provision | -$1.75M | -$271.00K | -$271.00K | -$368.00K | -544.3% |
| Net income | -$20.70M | -$26.78M | -$20.46M | -$25.01M | +22.7% |
| Net income to common | -$20.70M | -$26.78M | -$20.46M | -$25.01M | +22.7% |
| Basic EPS | -18.90 | — | -11.25 | -18.88 | — |
| Diluted EPS | -18.90 | — | -56.15 | -93.05 | — |
| EBIT | -$14.22M | -$28.46M | -$24.15M | -$25.40M | +50.0% |
| EBITDA | -$13.28M | -$26.59M | -$22.28M | -$23.53M | +50.1% |
| Basic shares | 1.10M | — | 1.84M | 1.32M | — |
| Diluted shares | 1.10M | — | 1.84M | 1.32M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.34M | $1.66M | $5.24M | $7.36M | +162.2% |
| Cash & short-term investments | $4.34M | $1.66M | $5.24M | $7.36M | +162.2% |
| Accounts receivable | — | $0 | $1.00K | $0 | — |
| Total current assets | $4.93M | $6.14M | $10.77M | $9.45M | -19.7% |
| Goodwill & intangibles | $1.09M | $15.40M | $17.27M | $19.14M | -92.9% |
| Total assets | $6.06M | $21.59M | $28.08M | $35.89M | -71.9% |
| Total current liabilities | $14.05M | $25.80M | $7.57M | $6.73M | -45.5% |
| Current debt | $396.00K | $634.00K | $1.80M | $1.84M | -37.5% |
| Total debt | $396.00K | $634.00K | $1.80M | $1.84M | -37.5% |
| Total liabilities | $14.36M | $31.60M | $16.03M | $17.61M | -54.6% |
| Retained earnings | -$134.83M | -$115.13M | -$89.08M | -$68.62M | -17.1% |
| Shareholder equity | -$8.30M | -$10.02M | $12.05M | $18.27M | +17.1% |
| Working capital | -$9.12M | -$19.65M | $3.21M | $2.72M | +53.6% |
| Net tangible assets | -$9.39M | -$25.42M | -$5.22M | -$864.00K | +63.1% |
| Shares issued | 809.42M | 332.85M | 228.03M | 138.76M | +143.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$20.70M | -$26.78M | -$20.46M | -$25.01M | +22.7% |
| Depreciation & amortisation | $934.00K | $1.87M | $1.87M | $1.87M | -50.0% |
| Stock-based compensation | $653.00K | $533.00K | $1.16M | $1.68M | +22.5% |
| Change in working capital | -$3.01M | $10.00M | $4.33M | $862.00K | -130.1% |
| Operating cash flow | -$13.28M | -$9.58M | -$15.16M | -$22.76M | -38.6% |
| Investing cash flow | — | $0 | $0 | -$2.37M | — |
| Financing cash flow | $15.98M | $5.99M | $12.97M | $3.73M | +167.0% |
| Free cash flow | -$13.28M | -$9.58M | -$15.16M | -$22.76M | -38.6% |
| End cash position | $4.34M | $1.66M | $5.24M | $7.36M | +162.2% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $69.46M | $4.34M | +1,498.6% |
| Cash & short-term investments | $69.46M | $4.34M | +1,498.6% |
| Total current assets | $69.99M | $4.93M | +1,318.4% |
| Goodwill & intangibles | $1.09M | $1.09M | -0.0% |
| Total assets | $71.11M | $6.06M | +1,073.3% |
| Total current liabilities | $24.37M | $14.05M | +73.4% |
| Current debt | $98.81K | $396.00K | -75.0% |
| Total debt | $98.81K | $396.00K | -75.0% |
| Total liabilities | $24.65M | $14.36M | +71.6% |
| Retained earnings | -$145.61M | -$134.83M | -8.0% |
| Shareholder equity | $46.47M | -$8.30M | +659.8% |
| Working capital | $45.61M | -$9.12M | +600.2% |
| Net tangible assets | $45.38M | -$9.39M | +583.4% |
| Shares issued | 5.67B | 809.42M | +600.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
3.29
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
-46.0% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
34
Contracts, this expiry
Put volume
112
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
7.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -0.02 | 1 | $676.98K | -64.4% |
| Next year | -0.02 | 1 | $642.00K | -5.2% |
Analyst targets & ownership
Mean target$28.33
High target$39.18
Low target$17.47
Implied upside205.91%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy2 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders15.42%
Held by institutions31.70%
Institutions holding41
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.53
-2.78% from price
SMA 20
10.19
-9.16% from price
SMA 50
12.02
-22.96% from price
SMA 100
12.56
-26.27% from price
SMA 200
10.47
-11.56% from price
EMA 12
9.78
-5.33% from price
EMA 26
10.63
-12.86% from price
EMA 50
11.44
-19.07% from price
RSI (14)
34.5
Neutral
MACD (12,26,9)
-0.85
Hist -0.01
ATR (14)
0.68
7.30% of price
Realised vol 30D
99.5%
Annualised
Bollinger upper
11.71
20, 2σ
Bollinger lower
8.68
20, 2σ
50 / 200 cross
Golden
12.02 vs 10.47
Trend bias
Below 200
-11.56%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.24
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
99.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-68.2%
Peak to trough
Max drawdown 5Y
-99.5%
Peak to trough
ATR 14
0.68
7.30% of price
Beta (reported)
2.27
5Y monthly, from filing
Short interest
Shares short
769.53K
Prior 559.16K
Change vs prior
+37.6%
Shorts adding
% of float
4.95%
Normal
% of shares out
4.95%
Against total outstanding
Days to cover
2.3
Liquid
Float
9.39M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 1, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Jul 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 1, 26 | BTIG | INITIATED | — | Buy |
| Jun 11, 26 | Lake Street | INITIATED | — | Buy |
| Apr 15, 26 | Laidlaw & Co. | INITIATED | — | Buy |
| Jan 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 12, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 2, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| Jul 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 11, 25 | Maxim Group | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJul 14, 2017
Last split1:5
Split dateApr 17, 2025
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-07-28
Corporate Changes & Voting Matters
6-K · 2026-06-02
Corporate Changes & Voting Matters
6-K · 2026-04-27
Corporate Changes & Voting Matters
6-K · 2026-03-31
Corporate Changes & Voting Matters
6-K · 2026-03-30
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-03-26
Offering Registrations
F-3 · 2026-03-18
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2025-12-22
Headlines
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
PR Newswire · 15d ago
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
CNW Group · 15d ago
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
PR Newswire · 15d ago
Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate
Simply Wall St. · 17d ago
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
CNW Group · 28d ago
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
PR Newswire · 28d ago
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
PR Newswire · 28d ago
Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?
Insider Monkey · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.